Prelude Capital Management’s Co-Diagnostics CODX Stock Holding History

Prelude Capital Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-573	Closed	-$106K	–	1836
2022 Q1	$106K	Buy	+573	New	+$119K	﹤0.01%	1400
2020 Q3	–	Sell	-27	Closed	-$15K	–	1895
2020 Q2	$15K	Buy	+27	New	+$12.3K	﹤0.01%	1459

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's CODX Position: Q2 2022 in Review

Prelude Capital Management sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 573 shares — an estimated $106K sold.

Prelude Capital Management first reported a position in CODX in Q2 2020 and held it in 2 quarters. The position peaked at $106K in Q1 2022. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

Prelude Capital Management reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
Prelude Capital Management sold 573 Co-Diagnostics shares in Q2 2022, an estimated $106K.
Prelude Capital Management first reported a position in Co-Diagnostics in Q2 2020 and held it in 2 quarters.
Prelude Capital Management's Co-Diagnostics position peaked at $106K in Q1 2022.
69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.